PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer

Despite the promising activity of poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in many cancer types with defects in the DNA damage response the majority of the treated patients acquire PARPi resistance and succumb to their diseases. Consequently, there is an urgent need to identify the mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Martincuks, Antons, Song, Jieun, Kohut, Adrian, Zhang, Chunyan, Li, Yi-Jia, Zhao, Qianqian, Mak, Edward, Rodriguez-Rodriguez, Lorna, Yu, Hua, Cristea, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693573/
https://www.ncbi.nlm.nih.gov/pubmed/34956861
http://dx.doi.org/10.3389/fonc.2021.724104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693573/
https://www.ncbi.nlm.nih.gov/pubmed/34956861
http://dx.doi.org/10.3389/fonc.2021.724104

Ejemplares similares